P21 is a synthetic peptide designed as a mimetic of ciliary neurotrophic factor (CNTF), a neurotrophin involved in neuronal survival, synaptic maintenance, and central repair pathways.
While native CNTF is a large protein with limited permeability and complex receptor interactions, P21 distills CNTF’s key functional domains into a short, bioactive sequence engineered for stability and targeted signaling [1].
One of the biggest advantages of P21 is its ability to cross the blood–brain barrier (BBB). Its small molecular size allows it to access central nervous system tissues more efficiently than full-length neurotrophic proteins [2].
This distinguishes P21 from broader neurotrophic blends such as cerebrolysin, which rely on multi-peptide mixtures and indirect peripheral effects [3].
Cerebrolysin contains fragments derived from porcine brain proteins and act through diffuse signaling. P21, in contrast, is a receptor-specific mimetic designed to emulate a single neurotrophin’s core actions.
P21’s ability to activate CNTF-related neurotrophic pathways can help support neuronal growth, differentiation, and long-term structural adaptability.
A core feature of P21’s activity is promoting neurogenesis, especially within brain regions where adult neural stem cells remain active [4].
P21 also interacts with pathways involved in synaptic plasticity, the process by which neurons strengthen, weaken, or remodel their connections in response to new information [2].
Because P21 is small enough to cross the blood–brain barrier, these effects occur in a more targeted and timely fashion.
P21 has attracted scientific interest for its potential relevance to pathways implicated in Alzheimer’s disease.
P21’s interaction with STAT3 and other CNTF-responsive intracellular cascades may help reinforce processes that protect neurons from [5]:
all hallmarks frequently in Alzheimer’s models.
Another area of interest is P21’s potential influence on amyloid- and tau-associated stress responses.
An in vivo study in a 3xTg-AD transgenic mouse model of Alzheimer’s disease evaluated effects of 12 months of chronic oral P21.
Female 3xTg-AD mice and wild-type controls were given P21 in their diet for 12 months, starting at 9-10 months of age when AD symptoms developed [6]. P21 diets resulted in:
These findings support P21 as a promising neurotrophic peptide mimetic with therapeutic potential to shift Alzheimer’s disease pathology from neurodegeneration toward regeneration.
P21 has also generated interest in research exploring neurodevelopmental pathways, because CNTF signaling plays a role in neuronal differentiation, axonal guidance, and early circuit formation [7].
During development, CNTF influences how neural progenitors mature into functional neurons and how connections between brain regions are refined.
A combined in vitro/in vivo study evaluated the therapeutic potential of P21 in a mouse model of CDKL5 deficiency disorder (CDD) [8].
CDD is an X-linked disorder that results in seizures, developmental and intellectual delays, and usually requires lifelong care. P21 administration resulted in:
There were limited effects in vivo, as P21 resulted in minimal behavioral improvement. This could be due to differences in bioavailability, timing, or developmental windows between in vitro and in vivo systems.
P21 is not just limited to rare neurodevelopmental disorders.
Prenatal to early postnatal treatment with the CNTF-derived peptide mimetic P021 was tested in Ts65Dn mice, a Down syndrome model that also develops Alzheimer’s-like memory deficits [9].
Early P021 intervention rescued developmental delays in pups and restored hippocampus-dependent memory in adulthood. The treatment:
These results demonstrate that enhancing neurotrophic support during critical periods of early brain development can prevent lifelong cognitive impairment and Alzheimer’s-like pathology associated with trisomy 21.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). P21 is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes five independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 4-panel testing protocol: HPLC purity analysis, ESI-MS identity confirmation, LAL endotoxin screening, and amino acid analysis (for peptides >15 residues). Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders placed before noon PST, Monday–Saturday, ship the same day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and amino acid analysis where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 10+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.